Skip to main content
Fig. 1 | Trials

Fig. 1

From: Resource and infrastructure challenges on the RESIST-2 Trial: an implementation study of drug resistance genotype-based algorithmic ART switches in HIV-2-infected adults in Senegal

Fig. 1

Algorithm for HIV-2 care in the RESIST-2 Trial for genotype-informed second-line therapy in Senegal. Bracketed steps are ISAARV Standard of Care for HIV-2 infection. Steps in gray box represent RESIST-2 Trial of DBS-based drug resistance genotyping to guide second-line therapy decisions. NRTI nucleoside reverse transcriptase inhibitor; PI protease inhibitor; 3TC lamivudine; AZT zidovudine; DRV/r ritonavir-boosted darunavir; LPV/r ritonavir-boosted lopinavir; RAL raltegravir; TDF tenofovir disoproxil fumarate. *Indicates twice-daily dosing

Back to article page

Trials

ISSN: 1745-6215